CL2011002315A1 - Compuestos derivados de pirimidindiona fusionados con pirrol, moduladores de receptores trpa1; composicion farmaceutica; y uso para tratar el dolor cronico, dolor reumatoide artritico o dolor osteoartritico. - Google Patents
Compuestos derivados de pirimidindiona fusionados con pirrol, moduladores de receptores trpa1; composicion farmaceutica; y uso para tratar el dolor cronico, dolor reumatoide artritico o dolor osteoartritico.Info
- Publication number
- CL2011002315A1 CL2011002315A1 CL2011002315A CL2011002315A CL2011002315A1 CL 2011002315 A1 CL2011002315 A1 CL 2011002315A1 CL 2011002315 A CL2011002315 A CL 2011002315A CL 2011002315 A CL2011002315 A CL 2011002315A CL 2011002315 A1 CL2011002315 A1 CL 2011002315A1
- Authority
- CL
- Chile
- Prior art keywords
- pain
- pyrimidinedione
- fused
- pharmaceutical composition
- pyrrole
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title abstract 6
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 101100482465 Caenorhabditis elegans trpa-1 gene Proteins 0.000 title abstract 2
- 208000000094 Chronic Pain Diseases 0.000 title abstract 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 title abstract 2
- 230000002917 arthritic effect Effects 0.000 title abstract 2
- 230000003349 osteoarthritic effect Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 2
- 230000001052 transient effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN665MU2009 | 2009-03-23 | ||
| IN2212MU2009 | 2009-09-23 | ||
| IN2211MU2009 | 2009-09-23 | ||
| IN2891MU2009 | 2009-12-15 | ||
| IN2892MU2009 | 2009-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2011002315A1 true CL2011002315A1 (es) | 2012-04-09 |
Family
ID=42780198
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2011002315A CL2011002315A1 (es) | 2009-03-23 | 2011-09-20 | Compuestos derivados de pirimidindiona fusionados con pirrol, moduladores de receptores trpa1; composicion farmaceutica; y uso para tratar el dolor cronico, dolor reumatoide artritico o dolor osteoartritico. |
| CL2014001447A CL2014001447A1 (es) | 2009-03-23 | 2014-06-02 | Compuestos derivados de pirimidindiona fusionada con pirazol, moduladores de receptores trpa1; composicion farmaceutica y uso para el dolor cronico, dolor reumatoide artritico o dolor osteoartritico (div. sol. 2315-11) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014001447A CL2014001447A1 (es) | 2009-03-23 | 2014-06-02 | Compuestos derivados de pirimidindiona fusionada con pirazol, moduladores de receptores trpa1; composicion farmaceutica y uso para el dolor cronico, dolor reumatoide artritico o dolor osteoartritico (div. sol. 2315-11) |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9000159B2 (enExample) |
| EP (2) | EP2411393B1 (enExample) |
| JP (1) | JP5657638B2 (enExample) |
| KR (1) | KR20110132575A (enExample) |
| CN (1) | CN102361873B (enExample) |
| AP (1) | AP3280A (enExample) |
| AU (1) | AU2010227245B2 (enExample) |
| BR (1) | BRPI1013559A2 (enExample) |
| CA (1) | CA2756518A1 (enExample) |
| CL (2) | CL2011002315A1 (enExample) |
| DK (1) | DK2411393T3 (enExample) |
| EA (1) | EA023857B1 (enExample) |
| ES (2) | ES2456515T3 (enExample) |
| IL (1) | IL215178A (enExample) |
| MX (1) | MX2011009824A (enExample) |
| PE (1) | PE20120774A1 (enExample) |
| PL (1) | PL2411393T3 (enExample) |
| PT (1) | PT2411393E (enExample) |
| SG (1) | SG174402A1 (enExample) |
| SI (1) | SI2411393T1 (enExample) |
| UA (1) | UA108069C2 (enExample) |
| WO (1) | WO2010109287A1 (enExample) |
| ZA (1) | ZA201107648B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11655245B2 (en) | 2018-03-19 | 2023-05-23 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008019357A2 (en) | 2006-08-07 | 2008-02-14 | Ironwood Pharmaceuticals, Inc. | Indole compounds |
| ES2456515T3 (es) | 2009-03-23 | 2014-04-22 | Glenmark Pharmaceuticals S.A. | Derivados de pirimidindiona fusionados como moduladores de TRPA1 |
| KR101591153B1 (ko) | 2010-12-20 | 2016-02-02 | 그렌마크 파머수티칼스 에스. 아. | Trpa1 길항제로서의 2-아미노-4-아릴티아졸 화합물 |
| AR084433A1 (es) | 2010-12-22 | 2013-05-15 | Ironwood Pharmaceuticals Inc | Inhibidores de la faah y composiciones farmaceuticas que los contienen |
| EP2520566A1 (en) | 2011-05-06 | 2012-11-07 | Orion Corporation | New Pharmaceutical Compounds |
| RU2014100744A (ru) | 2011-06-13 | 2015-07-20 | Гленмарк Фармасьютикалс С.А. | Лечение респираторных нарушений с помощью trpa1 антагонистов |
| WO2012176105A1 (en) | 2011-06-22 | 2012-12-27 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist |
| JP2014517062A (ja) | 2011-06-22 | 2014-07-17 | グレンマーク ファーマシューティカルズ， エセ．アー． | ＴＲＰＡ１アンタゴニスト及びβ２アゴニストを含む医薬組成物 |
| US20140148423A1 (en) | 2011-07-25 | 2014-05-29 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition comprising a trpa1 antagonist and a steroid |
| KR20140073496A (ko) | 2011-08-09 | 2014-06-16 | 하이드라 바이오사이언시스, 인코포레이티드 | 일과성 수용체 잠재 이온채널 trpa1의 억제 |
| US20140364445A1 (en) | 2011-12-05 | 2014-12-11 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent |
| EP2805718B1 (en) | 2012-01-17 | 2018-04-04 | EA Pharma Co., Ltd. | Heterocyclic amide derivative and pharmaceutical product containing same |
| AU2013273118B2 (en) | 2012-06-08 | 2015-11-05 | Glenmark Pharmaceuticals S.A. | Amides of 2-amino-4-arylthiazole compounds and their salts |
| PE20150598A1 (es) | 2012-10-01 | 2015-05-20 | Orion Corp | Derivados de n-prop-2-inil carboxamida y su uso como antagonistas del receptor transitorio potencial de la subfamilia a, miembro 1 |
| US9394308B2 (en) | 2013-01-18 | 2016-07-19 | Merck Sharp & Dohme Corp. | Inhibiting the transient receptor potential A1 ion channel |
| MX2016004741A (es) | 2013-10-15 | 2016-07-26 | Glenmark Pharmaceuticals Sa | Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico. |
| RU2674977C2 (ru) | 2013-10-30 | 2018-12-14 | Шанхай Хэнжуй Фармасьютикал Ко., Лтд. | Производные пиразолопиримидона или пирролотриазона, способ их получения и их фармацевтические применения |
| CN103755705B (zh) * | 2014-02-17 | 2017-02-15 | 上海佰特因医药科技有限公司 | 一种天然产物四甲基尿酸的全合成方法 |
| JP6667092B2 (ja) * | 2014-08-11 | 2020-03-18 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ | ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体 |
| WO2016042501A1 (en) | 2014-09-16 | 2016-03-24 | Glenmark Pharmaceuticals S.A. | Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain |
| CN105001170A (zh) * | 2015-07-13 | 2015-10-28 | 佛山市赛维斯医药科技有限公司 | 末端腈基取代的三氮唑亚砜类化合物、其制备方法及其用途 |
| WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
| WO2017064068A1 (en) | 2015-10-14 | 2017-04-20 | Almirall, S.A. | New trpa1 antagonists |
| AU2018305633B2 (en) * | 2017-07-28 | 2022-11-24 | Jiangsu Hengrui Medicine Co., Ltd. | Method for preparing pyrimidone heteroaryl derivative and intermediate of pyrimidone heteroaryl derivative |
| CN109422749B (zh) * | 2017-08-21 | 2023-01-24 | 重庆医药工业研究院有限责任公司 | 一种抑制单羧酸转运蛋白的嘧啶二酮衍生物 |
| CN108558836A (zh) * | 2018-05-14 | 2018-09-21 | 东南大学 | 一类具有双重作用机制的dpp-4抑制剂及其用途 |
| WO2023096915A1 (en) * | 2021-11-24 | 2023-06-01 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| US20250136587A1 (en) * | 2022-02-03 | 2025-05-01 | D. E. Shaw Research, Llc | N3-substituted uracil compounds as trpa1 inhibitors |
| US20250214980A1 (en) | 2022-03-14 | 2025-07-03 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| CN114656472B (zh) * | 2022-04-27 | 2023-07-04 | 成都施贝康生物医药科技有限公司 | 吡唑并嘧啶类化合物、异构体或盐及其制备方法和用途 |
| CN114656473B (zh) * | 2022-04-27 | 2023-09-29 | 成都施贝康生物医药科技有限公司 | 吡咯并嘧啶类化合物、异构体或盐及其制备方法和用途 |
| CN114656480B (zh) * | 2022-04-27 | 2024-01-26 | 成都施贝康生物医药科技有限公司 | 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途 |
| CN118373832B (zh) * | 2023-01-20 | 2025-01-28 | 深圳晶蛋生物医药科技有限公司 | 大环类化合物、其药物组合物及其应用 |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2248231A1 (de) | 1972-10-02 | 1974-04-11 | Basf Ag | 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine |
| SE9701398D0 (sv) | 1997-04-15 | 1997-04-15 | Astra Pharma Prod | Novel compounds |
| ES2193839B1 (es) | 2001-06-22 | 2005-02-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de 6-fenildihidropirrolpirimidindiona. |
| AU2003253165A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| WO2004055054A1 (en) | 2002-12-18 | 2004-07-01 | Novartis Ag | Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons |
| EP1713815A4 (en) | 2004-02-11 | 2009-03-11 | Smithkline Beecham Corp | PTH AGONISTS |
| WO2005089206A2 (en) | 2004-03-13 | 2005-09-29 | Irm Llc | Modulators of ion channel trpa1 |
| MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| JPWO2006083005A1 (ja) | 2005-02-03 | 2008-06-26 | 武田薬品工業株式会社 | 縮合ピリミジン誘導体およびその用途 |
| US20060291462A1 (en) * | 2005-06-28 | 2006-12-28 | Utstarcom, Inc. | Method and apparatus using multiple application cards to comprise multiple logical network entities |
| EP1962855B1 (en) * | 2005-12-22 | 2013-08-21 | Hydra Biosciences, Inc. | Trpa1 inhibitors for treating pain |
| TW200800997A (en) | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
| WO2008094909A2 (en) | 2007-01-29 | 2008-08-07 | Xenon Pharmaceuticals Inc. | Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions |
| WO2009002933A1 (en) * | 2007-06-22 | 2008-12-31 | Hydra Biosciences, Inc. | Methods and compositions for treating disorders |
| WO2009158719A2 (en) | 2008-06-27 | 2009-12-30 | Hydra Biosciences, Inc. | Methods and compositions for treating disorders |
| US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| BRPI1009372A2 (pt) | 2009-03-23 | 2016-05-31 | Glenmark Pharmaceuticals Sa | compostos, composição farmacêutica e respectivos usos |
| ES2456515T3 (es) | 2009-03-23 | 2014-04-22 | Glenmark Pharmaceuticals S.A. | Derivados de pirimidindiona fusionados como moduladores de TRPA1 |
| PE20120834A1 (es) | 2009-03-23 | 2012-07-25 | Glenmark Pharmaceuticals Sa | Derivados de furopirimidindiona como moduladores de trpa1 |
| AR076332A1 (es) | 2009-04-21 | 2011-06-01 | Boehringer Ingelheim Int | Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones. |
| CN102802416A (zh) | 2009-06-18 | 2012-11-28 | 巴斯夫欧洲公司 | 杀真菌混合物 |
| US8404461B2 (en) | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| AU2010308028A1 (en) | 2009-10-15 | 2012-04-19 | Pfizer Inc. | Pyrrolo[2,3-d] pyrimidine compounds |
| AR078522A1 (es) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
| EP2311844A1 (en) | 2009-10-15 | 2011-04-20 | Interquim, S.A. | Silyl polymeric benzoic acid ester compounds, uses, and compositions thereof |
| US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| CN102666507B (zh) | 2010-07-13 | 2014-09-17 | 诺华股份有限公司 | 噁嗪衍生物及其在治疗神经病症中的用途 |
-
2010
- 2010-03-17 ES ES10755503.9T patent/ES2456515T3/es active Active
- 2010-03-17 ES ES13005523.9T patent/ES2551085T3/es active Active
- 2010-03-17 MX MX2011009824A patent/MX2011009824A/es unknown
- 2010-03-17 EP EP10755503.9A patent/EP2411393B1/en not_active Not-in-force
- 2010-03-17 DK DK10755503.9T patent/DK2411393T3/da active
- 2010-03-17 JP JP2012501401A patent/JP5657638B2/ja not_active Expired - Fee Related
- 2010-03-17 PL PL10755503T patent/PL2411393T3/pl unknown
- 2010-03-17 AP AP2011005887A patent/AP3280A/xx active
- 2010-03-17 SG SG2011066487A patent/SG174402A1/en unknown
- 2010-03-17 CN CN201080013471.6A patent/CN102361873B/zh not_active Expired - Fee Related
- 2010-03-17 BR BRPI1013559A patent/BRPI1013559A2/pt active Search and Examination
- 2010-03-17 EP EP13005523.9A patent/EP2708538B1/en not_active Not-in-force
- 2010-03-17 UA UAA201111147A patent/UA108069C2/uk unknown
- 2010-03-17 WO PCT/IB2010/000553 patent/WO2010109287A1/en not_active Ceased
- 2010-03-17 AU AU2010227245A patent/AU2010227245B2/en not_active Ceased
- 2010-03-17 KR KR1020117022612A patent/KR20110132575A/ko not_active Ceased
- 2010-03-17 PE PE2011001707A patent/PE20120774A1/es not_active Application Discontinuation
- 2010-03-17 CA CA2756518A patent/CA2756518A1/en not_active Abandoned
- 2010-03-17 EA EA201190143A patent/EA023857B1/ru not_active IP Right Cessation
- 2010-03-17 SI SI201030523T patent/SI2411393T1/sl unknown
- 2010-03-17 PT PT107555039T patent/PT2411393E/pt unknown
-
2011
- 2011-09-15 IL IL215178A patent/IL215178A/en not_active IP Right Cessation
- 2011-09-20 CL CL2011002315A patent/CL2011002315A1/es unknown
- 2011-10-19 ZA ZA2011/07648A patent/ZA201107648B/en unknown
-
2013
- 2013-11-14 US US14/079,932 patent/US9000159B2/en not_active Expired - Fee Related
-
2014
- 2014-06-02 CL CL2014001447A patent/CL2014001447A1/es unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11655245B2 (en) | 2018-03-19 | 2023-05-23 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
| US12202824B2 (en) | 2018-03-19 | 2025-01-21 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014001447A1 (es) | Compuestos derivados de pirimidindiona fusionada con pirazol, moduladores de receptores trpa1; composicion farmaceutica y uso para el dolor cronico, dolor reumatoide artritico o dolor osteoartritico (div. sol. 2315-11) | |
| CL2008000825A1 (es) | Compuestos heterociclicos derivados de quinolincarboxamidas utiles como antagonistas de p2x7; su metodo de preparacion; la composicion farmaceutica que lo contiene; el emtodo de preparacion de la composicion; y el uso de los mismos para preparar medicamentos utiles en artritis reumatoide. | |
| CL2011000087A1 (es) | Compuestos derivados de heteroarilo sustituido, inhibidores de los receptores dgat1; composicion farmaceutica; y su uso para tratar la diabetes tipo ll y obesidad. | |
| EA201370066A1 (ru) | Модуляторы эстрогеновых рецепторов и их применение | |
| CL2008002319A1 (es) | Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer. | |
| MA32703B1 (fr) | Combinaison d'une insuline et d'un agoniste de glp 1 | |
| BRPI0917315A2 (pt) | anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica | |
| CL2011002877A1 (es) | Anticuerpo que reconoce el dominio fnd1 del receptor ax1; composicion farmaceutica que lo comprende; y su uso para tratar cancer. | |
| CL2007003726A1 (es) | Anticuerpos anti-receptor del factor del crecimiento similar a la insulina i (igf-ir); composicion farmaceutica que lo contiene; y su uso para tratar el cancer. | |
| CL2013001107A1 (es) | Polipeptido derivado de la il-2 con actividad agonista; proteina de fusion que lo comprende; composicion farmaceutica que lo comprende; y su uso para tratar cancer y enfermedades infecciosas cronicas. | |
| CL2008000467A1 (es) | Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma | |
| CL2007003226A1 (es) | Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer. | |
| SV2006002167A (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol- oxindol y sus usos ref. am101791 | |
| CL2013001783A1 (es) | Analogos de glucagon que presentan actividad potente en receptor de gip; dimero o multidimero; conjugado; composicion farmaceutica que los comprende; y sus usos en tratar diabetes u obesidad. | |
| BRPI0908131A2 (pt) | Uso de vídeo com disparadores para identificação de conteúdo anterativo | |
| CL2008000094A1 (es) | Compuestos derivados de pteridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para aumentar la vasodilatacion. | |
| CL2007000311A1 (es) | Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende;y su uso en el trastamiento de un trastorno proliferativos como es el cancer. | |
| BRPI0817462A2 (pt) | Uso de um aditivo em uma composição de combustível diesel. | |
| BRPI1005322A2 (pt) | anticorpo, composição farmacêutica e uso de pelo menos um anticorpo | |
| CL2011000501A1 (es) | Composición farmacéutica que comprende un agonista de gpr119 en combinación con un inhibidor de dpp-4 seleccionado de un grupo definido; uso para prevenir y/o tratar enfermedades metabólicas, como resistencia insulinica, diabetes, sindrome metabolico, obesidad, hiperlipidemia, osteoporosis, entre otras. | |
| BRPI1007018A2 (pt) | composto, composição farmacêutica, e , uso de um composto. | |
| CL2007002316A1 (es) | Compuestos derivados de pirimidina, inhibidores de pi3k; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades proliferativas como cancer. | |
| CL2008002041A1 (es) | Compuestos derivados de piperidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar ansiedad. | |
| CL2011001464A1 (es) | Compuestos derivados de purina, agonistas del receptor cb2; composicion farmaceutica que los comprende; y uso del compuesto para tratar el dolor osteoartritico. | |
| CL2013002053A1 (es) | Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct |